ANI Pharmaceuticals ANIP Generics and Other — Selling, General and Administrative Expense

Other segment segments

Similar metrics at other companies

CHE

CHEOther Selling General And Administrative Expense

$36.73M+14.0%

SRPTAll Other Segments — Selling General And Administrative Expense

$40.19M-21.4%

DJT

DJTSelling General And Administrative Expense

$37.94M+50.7%

WMAll Other Segments — Selling General And Administrative Expense

$29M-3.3%

NWSAOther — Selling, General and Administrative Expense

$47M-25.4%

SYYOther — Selling, general & administrative expense

$32M+6.7%

Questions, answered.

What is ANI Pharmaceuticals's generics and other — selling, general and administrative expense?

ANI Pharmaceuticals (ANIP) reported generics and other — selling, general and administrative expense of $1.52M in Q1 2026.

How has ANI Pharmaceuticals's generics and other — selling, general and administrative expense changed year-over-year?

ANI Pharmaceuticals's generics and other — selling, general and administrative expense increased by 8.1% year-over-year, from $1.41M to $1.52M.

What is the long-term trend for ANI Pharmaceuticals's generics and other — selling, general and administrative expense?

Over 3 years (2022 to 2025), ANI Pharmaceuticals's generics and other — selling, general and administrative expense has grown at a 12.7% compound annual growth rate (CAGR), from $3.96M to $5.68M.

What does generics and other — selling, general and administrative expense mean?

Encompasses the overhead costs related to the management, marketing, and administrative support functions dedicated to the generics business segment. It provides insight into the operational leverage and the cost structure required to support the segment's commercial activities.